Miracle Shot Crushes Obesity Records

person in white tank top showing loose jeans waistband — Photo: Maslowski Marcin / Shutterstock

A new experimental shot has pushed body weight down by nearly a quarter in a year-long study, putting it ahead of every weight-loss drug sold today.

At a Glance

Retatrutide, a triple-hormone drug, cut body weight by up to 24.2% over 48 weeks in a placebo-controlled trial
The same drug slashed liver fat by more than 80% in patients with fatty liver disease
Unlike current shots that hit one or two hormone targets, retatrutide works on three at once: GLP-1, GIP, and glucagon
Amylin-based drugs are now in early human testing and could become the next addition to this drug category
Eli Lilly has moved retatrutide into Phase 3 trials, the final step before it can seek approval from the Food and Drug Administration (FDA)

A Triple-Hormone Drug Delivers Record Weight Loss

A 48-week study tested retatrutide against a placebo in people with obesity. Participants who took the 8 mg dose lost an average of 22.8% of their body weight. Those on the 12 mg dose lost 24.2%. The trial, registered as NCT04881760, was randomized and double-blind, the gold standard for drug testing. Those numbers put retatrutide ahead of every GLP-1 drug currently sold in pharmacies.

Researchers published the full results in Nature Medicine in June 2024. The study focused on patients with metabolic dysfunction-associated steatotic liver disease, a fancy name for fatty liver tied to obesity. That disease affects millions of Americans and often goes undiagnosed until serious damage has already occurred.

Liver Fat Vanishes in Most Patients

Beyond weight loss, the drug produced a dramatic drop in liver fat. At 24 weeks, patients on the 8 mg dose saw liver fat drop by 81.4% on average. Those on 12 mg saw an 82.4% drop. Liver fat returned to normal levels in 79% of patients on the lower dose and 86% on the higher dose. Doctors involved in the research called the results some of the strongest ever recorded for liver fat reduction in a clinical trial.

Fatty liver disease often leads to cirrhosis and liver failure if left untreated. A drug that reverses it while also shrinking waistlines offers a two-for-one benefit that current obesity treatments have not matched. That combination is why researchers are watching this drug class so closely.

How Retatrutide Works Differently

Current blockbuster drugs like Ozempic and Wegovy target one hormone receptor, GLP-1. Tirzepatide, sold as Zepbound, hits two: GLP-1 and GIP. Retatrutide goes further by activating a third target, the glucagon receptor, alongside GLP-1 and GIP. That third hormone is believed to boost calorie burning on top of appetite suppression, which may explain the larger weight-loss numbers seen in trials.

Weight loss at this scale starts to approach what patients see after bariatric surgery, according to researchers at Yale School of Medicine. That comparison matters because surgery carries real risks and recovery time that many patients want to avoid. A shot that gets close to surgical results without an operating room could change how doctors treat severe obesity.

The Next Wave: Amylin and Beyond

Retatrutide is not the only new approach in the pipeline. Drug makers are also testing amylin-based compounds, which work through yet another hormone pathway tied to appetite and fullness. These amylin drugs remain in earlier stages of human testing, but early signals suggest they could eventually join GLP-1 drugs as another option for patients and doctors to choose from.

Most powerful obesity drug yet: People lost up to 25% of weight in trial | Beth Mole, Ars Technica

Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with… pic.twitter.com/KDkluz3APe

— Owen Gregorian (@OwenGregorian) September 30, 2026

Eli Lilly, the company developing retatrutide, has since advanced the drug into Phase 3 trials, the last stage of testing before a company can ask the FDA for approval. The company has reported successful results in additional obesity trials beyond the original study. No drug is approved until the FDA finishes its review, and the public still awaits that decision. For the millions of Americans managing obesity and diabetes without relying on costly surgery or lifelong prescriptions with uncertain payoffs, that review can’t come soon enough.